The Filings Report

CVS Health

CVSNYSECIK 64803Consumer Defensive / Grocery & Drug Storesfiscal year ends December73 quarters since 2008

Revenue, Q2 FY2026
$106.1B
+7.3% on Q2 FY2025
Net income
$3.0B
+191.8% on Q2 FY2025
Free cash flow
$5.7B
+338.3% on Q2 FY2025
Diluted EPS
$2.31
+188.8% on Q2 FY2025
Revenue, TTM
$415.1B
trailing four quarters
Net margin, TTM
1.2%
net income $4.9B
Free cash flow, TTM
$11.8B
$14.8B less $3.0B capex
Cash and equivalents
$11.3B
long-term debt —, Jun 30, 2026
Shares, 12-month change
+0.8%
1.28B shares, Jun 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
$3.4B
3.0% of market value
Market value
$115.4B
at the close, buybacks

Latest quarter Q2 FY2026, filed August 5, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q2 FY2026, the quarter ended June 30, 2026, CVS Health reported revenue of $106.1B, +7.3% on Q2 FY2025, and net income of $3.0B (+191.8%). Operating margin was 4.4%. Free cash flow, operating cash flow less capital expenditures, was $5.7B ($6.3B less $691M). Diluted earnings per share were $2.31.

The last 16 quarters

Q3 FY2022 to Q2 FY2026, through the filing of August 5, 2026.

Revenue and net incomeRevenueNet income
−$50B$0$50B$100B$150BQ3'22, Revenue: $81.2BQ3'22, Net income: −$3.4BQ3'22Q4'22, Revenue: $83.8BQ4'22, Net income: $2.3BQ4'22Q1'23, Revenue: $85.3BQ1'23, Net income: $2.1BQ1'23Q2'23, Revenue: $88.9BQ2'23, Net income: $1.9BQ2'23Q3'23, Revenue: $89.8BQ3'23, Net income: $2.3BQ3'23Q4'23, Revenue: $93.8BQ4'23, Net income: $2.0BQ4'23Q1'24, Revenue: $88.4BQ1'24, Net income: $1.1BQ1'24Q2'24, Revenue: $91.2BQ2'24, Net income: $1.8BQ2'24Q3'24, Revenue: $95.4BQ3'24, Net income: $87MQ3'24Q4'24, Revenue: $97.7BQ4'24, Net income: $1.6BQ4'24Q1'25, Revenue: $94.6BQ1'25, Net income: $1.8BQ1'25Q2'25, Revenue: $98.9BQ2'25, Net income: $1.0BQ2'25Q3'25, Revenue: $102.9BQ3'25, Net income: −$4.0BQ3'25Q4'25, Revenue: $105.7BQ4'25, Net income: $2.9BQ4'25Q1'26, Revenue: $100.4BQ1'26, Net income: $2.9BQ1'26Q2'26, Revenue: $106.1BQ2'26, Net income: $3.0BQ2'26−$50B$0$50B$100B$150BQ3'22, Revenue: $81.2BQ3'22, Net income: −$3.4BQ4'22, Revenue: $83.8BQ4'22, Net income: $2.3BQ4'22Q1'23, Revenue: $85.3BQ1'23, Net income: $2.1BQ2'23, Revenue: $88.9BQ2'23, Net income: $1.9BQ2'23Q3'23, Revenue: $89.8BQ3'23, Net income: $2.3BQ4'23, Revenue: $93.8BQ4'23, Net income: $2.0BQ4'23Q1'24, Revenue: $88.4BQ1'24, Net income: $1.1BQ2'24, Revenue: $91.2BQ2'24, Net income: $1.8BQ2'24Q3'24, Revenue: $95.4BQ3'24, Net income: $87MQ4'24, Revenue: $97.7BQ4'24, Net income: $1.6BQ4'24Q1'25, Revenue: $94.6BQ1'25, Net income: $1.8BQ2'25, Revenue: $98.9BQ2'25, Net income: $1.0BQ2'25Q3'25, Revenue: $102.9BQ3'25, Net income: −$4.0BQ4'25, Revenue: $105.7BQ4'25, Net income: $2.9BQ4'25Q1'26, Revenue: $100.4BQ1'26, Net income: $2.9BQ2'26, Revenue: $106.1BQ2'26, Net income: $3.0BQ2'26

Net income losses drawn in red.

Free cash flow
−$5B$0$5B$10BQ3'22, Free cash flow: $8.5BQ3'22Q4'22, Free cash flow: −$2.6BQ4'22Q1'23, Free cash flow: $6.5BQ1'23Q2'23, Free cash flow: $5.3BQ2'23Q3'23, Free cash flow: $2.2BQ3'23Q4'23, Free cash flow: −$3.5BQ4'23Q1'24, Free cash flow: $4.2BQ1'24Q2'24, Free cash flow: $2.5BQ2'24Q3'24, Free cash flow: −$1.4BQ3'24Q4'24, Free cash flow: $1.1BQ4'24Q1'25, Free cash flow: $3.8BQ1'25Q2'25, Free cash flow: $1.3BQ2'25Q3'25, Free cash flow: $98MQ3'25Q4'25, Free cash flow: $2.6BQ4'25Q1'26, Free cash flow: $3.4BQ1'26Q2'26, Free cash flow: $5.7BQ2'26−$5B$0$5B$10BQ3'22, Free cash flow: $8.5BQ4'22, Free cash flow: −$2.6BQ4'22Q1'23, Free cash flow: $6.5BQ2'23, Free cash flow: $5.3BQ2'23Q3'23, Free cash flow: $2.2BQ4'23, Free cash flow: −$3.5BQ4'23Q1'24, Free cash flow: $4.2BQ2'24, Free cash flow: $2.5BQ2'24Q3'24, Free cash flow: −$1.4BQ4'24, Free cash flow: $1.1BQ4'24Q1'25, Free cash flow: $3.8BQ2'25, Free cash flow: $1.3BQ2'25Q3'25, Free cash flow: $98MQ4'25, Free cash flow: $2.6BQ4'25Q1'26, Free cash flow: $3.4BQ2'26, Free cash flow: $5.7BQ2'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$5B$10B$15B$20BQ3'22, Cash and equivalents: $17.2BQ3'22Q4'22, Cash and equivalents: $12.9BQ4'22Q1'23, Cash and equivalents: $14.6BQ1'23Q2'23, Cash and equivalents: $13.8BQ2'23Q3'23, Cash and equivalents: $13.0BQ3'23Q4'23, Cash and equivalents: $8.2BQ4'23Q1'24, Cash and equivalents: $9.8BQ1'24Q2'24, Cash and equivalents: $12.5BQ2'24Q3'24, Cash and equivalents: $6.9BQ3'24Q4'24, Cash and equivalents: $8.6BQ4'24Q1'25, Cash and equivalents: $10.1BQ1'25Q2'25, Cash and equivalents: $11.8BQ2'25Q3'25, Cash and equivalents: $9.1BQ3'25Q4'25, Cash and equivalents: $8.5BQ4'25Q1'26, Cash and equivalents: $9.5BQ1'26Q2'26, Cash and equivalents: $11.3BQ2'26$0$5B$10B$15B$20BQ3'22, Cash and equivalents: $17.2BQ4'22, Cash and equivalents: $12.9BQ4'22Q1'23, Cash and equivalents: $14.6BQ2'23, Cash and equivalents: $13.8BQ2'23Q3'23, Cash and equivalents: $13.0BQ4'23, Cash and equivalents: $8.2BQ4'23Q1'24, Cash and equivalents: $9.8BQ2'24, Cash and equivalents: $12.5BQ2'24Q3'24, Cash and equivalents: $6.9BQ4'24, Cash and equivalents: $8.6BQ4'24Q1'25, Cash and equivalents: $10.1BQ2'25, Cash and equivalents: $11.8BQ2'25Q3'25, Cash and equivalents: $9.1BQ4'25, Cash and equivalents: $8.5BQ4'25Q1'26, Cash and equivalents: $9.5BQ2'26, Cash and equivalents: $11.3BQ2'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

CVS Health income statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 10, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 12, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Revenue106,096100,426105,693102,87198,91594,58897,71095,428+7.3%
Cost of revenue58,86255,44459,06057,04554,00551,05755,26852,948+9.0%
Gross profit—————————
Research and development—————————
Selling, general and administrative—————————
Operating income4,7034,6802,112(3,207)2,3813,3742,368832+97.5%
Other income (expense)3132292629282525+6.9%
Pretax income3,9773,9381,354(3,482)1,6472,6172,126105+141.5%
Income tax982981(1,569)508——50334—
Net income2,9792,9432,943(3,975)1,0211,7791,64487+191.8%
Diluted EPS ($)2.312.30—(3.13)0.801.41—0.07+188.8%
Diluted shares (millions)1,2871,279—1,2691,2701,264—1,259—

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

CVS Health balance sheet, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 10, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 12, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Cash and equivalents11,3299,5428,4539,09811,78710,0768,5866,875−3.9%
Short-term investments2,6292,2602,1452,1342,3862,5782,4072,805+10.2%
Total current assets75,34674,81774,71477,10975,64973,19168,64567,343−0.4%
Total assets253,768252,974253,538255,327258,343255,585253,215252,427−1.8%
Total current liabilities87,04186,40688,69292,69594,16288,96184,60984,627−7.6%
Long-term debt—————————
Total liabilities173,869175,337178,156182,217180,792178,475177,485177,321−3.8%
Stockholders’ equity79,70277,45675,21472,92877,37976,92975,56074,944+3.0%
Shares outstanding (millions)1,2791,2761,2721,2691,2681,2651,2611,258—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q2 FY2026 filed August 5, 2026.

CVS Health cash flow statement, quarterly
Millions of dollarsQ2 FY2026ended Jun 30, 2026filed Aug 5, 2026Q1 FY2026ended Mar 31, 2026filed May 6, 2026Q4 FY2025ended Dec 31, 2025filed Feb 10, 2026Q3 FY2025ended Sep 30, 2025filed Oct 29, 2025Q2 FY2025ended Jun 30, 2025filed Jul 31, 2025Q1 FY2025ended Mar 31, 2025filed May 1, 2025Q4 FY2024ended Dec 31, 2024filed Feb 12, 2025Q3 FY2024ended Sep 30, 2024filed Nov 6, 2024YoYQ2 FY2026vs Q2 FY2025
Operating cash flow6,3454,2493,3907961,8974,5561,860(745)+234.5%
Capital expenditures691849784698607743768670+13.8%
Free cash flow (CFO − capex)5,6543,4002,606981,2903,8131,092(1,415)+338.3%
Depreciation and amortization1,1261,1151,1471,1341,1711,1541,1471,161−3.8%
Share repurchases——00000(1)—
Dividends paid878847845846866840838837+1.4%

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 10, 2026.

Income statement

CVS Health income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 10, 2026FY2024ended Dec 31, 2024filed Feb 12, 2025FY2023ended Dec 31, 2023filed Feb 7, 2024FY2022ended Dec 31, 2022filed Feb 8, 2023FY2021ended Dec 31, 2021filed Feb 9, 2022FY2020ended Dec 31, 2020filed Feb 16, 2021FY2019ended Dec 31, 2019filed Feb 18, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 14, 2018FY2016ended Dec 31, 2016filed Feb 9, 2017FY2015ended Dec 31, 2015filed Feb 9, 2016FY2014ended Dec 31, 2014filed Feb 10, 2015FY2013ended Dec 31, 2013filed Feb 11, 2014FY2012ended Dec 31, 2012filed Feb 15, 2013FY2011ended Dec 31, 2011filed Feb 17, 2012FY2010ended Dec 31, 2010filed Feb 18, 2011FY2009ended Dec 31, 2009filed Feb 26, 2010FY2008ended Dec 31, 2008filed Aug 4, 2009FY2007ended Dec 29, 2007filed Aug 4, 2009
Revenue402,067372,809357,776322,467292,111268,706256,776194,579184,786177,546153,290139,367126,761123,120107,08095,77898,21587,47276,330
Cost of revenue221,167206,287217,098196,892175,803163,981158,719156,447153,448146,533126,762114,000102,978100,63286,51875,55977,85769,18260,222
Gross profit————————28,54528,85726,52825,36723,78322,48820,56220,21920,35818,29016,108
Research and development———————————————————
Selling, general and administrative———————————————————
Operating income4,6608,51613,7437,95413,31013,91111,9874,0219,53810,3869,4758,7998,0377,2106,3316,1376,4256,0464,794
Other income (expense)11299881691822061244(208)(28)—————————
Pretax income2,1366,14811,1735,83610,5379,7708,9971,4068,2688,6378,6167,6787,5286,3055,7475,6015,9005,5374,359
Income tax4081,5622,8051,5092,5482,5692,3662,0021,6373,3173,3863,0332,9282,4362,2582,1792,2002,1931,722
Net income1,7684,6148,3444,3118,0017,1796,634(594)6,6225,3175,2374,644———3,4273,6963,1982,637
Diluted EPS ($)1.393.666.473.266.025.465.08(0.57)6.444.904.633.963.743.022.572.492.552.181.92
Diluted shares (millions)1,2711,2621,2901,3231,3291,3141,3051,0441,0241,0791,1261,1691,2261,2801,3471,3771,4501,4691,372

Balance sheet

CVS Health balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 10, 2026FY2024ended Dec 31, 2024filed Feb 12, 2025FY2023ended Dec 31, 2023filed Feb 7, 2024FY2022ended Dec 31, 2022filed Feb 8, 2023FY2021ended Dec 31, 2021filed Feb 9, 2022FY2020ended Dec 31, 2020filed Feb 16, 2021FY2019ended Dec 31, 2019filed Feb 18, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 14, 2018FY2016ended Dec 31, 2016filed Feb 9, 2017FY2015ended Dec 31, 2015filed Feb 9, 2016FY2014ended Dec 31, 2014filed Feb 10, 2015FY2013ended Dec 31, 2013filed Feb 11, 2014FY2012ended Dec 31, 2012filed Feb 15, 2013FY2011ended Dec 31, 2011filed Feb 17, 2012FY2010ended Dec 31, 2010filed Feb 18, 2011FY2009ended Dec 31, 2009filed Feb 26, 2010FY2008ended Dec 31, 2008filed Aug 4, 2009FY2007ended Dec 29, 2007filed Aug 4, 2009
Cash and equivalents8,4538,5868,19612,9459,4087,8545,6834,0591,6963,3712,4592,4814,0891,3751,4131,4271,0861,3521,056
Short-term investments2,1452,4073,2592,7783,1173,0002,3732,5221118788348855450—
Total current assets74,71468,64567,85865,63360,00856,36950,30245,19531,22931,04229,15825,98325,32520,16118,59417,70617,53716,526—
Total assets253,538253,215249,728228,275232,999230,715222,449216,66895,13194,46292,43774,18771,52666,22164,85262,16961,64160,960—
Total current liabilities88,69284,60979,18969,42167,80762,01753,30345,76230,64826,25023,16919,02715,42514,15011,95611,07012,30013,490—
Long-term debt——————64,69971,34822,18125,61526,26711,63012,8419,1339,2088,6528,7568,057—
Total liabilities178,156177,485173,092156,506157,618161,014158,279157,94757,449————————26,386—
Stockholders’ equity75,21475,56076,46171,46975,07569,38963,86458,40337,67836,83037,19637,95837,93837,653—37,70035,76834,57431,322
Shares outstanding (millions)1,2721,2611,2581,2841,3131,3111,3041,2971,0151,0261,0981,1251,1821,2311,3021,3681,391——

Cash flow statement

CVS Health cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 10, 2026FY2024ended Dec 31, 2024filed Feb 12, 2025FY2023ended Dec 31, 2023filed Feb 7, 2024FY2022ended Dec 31, 2022filed Feb 8, 2023FY2021ended Dec 31, 2021filed Feb 9, 2022FY2020ended Dec 31, 2020filed Feb 16, 2021FY2019ended Dec 31, 2019filed Feb 18, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 14, 2018FY2016ended Dec 31, 2016filed Feb 9, 2017FY2015ended Dec 31, 2015filed Feb 9, 2016FY2014ended Dec 31, 2014filed Feb 10, 2015FY2013ended Dec 31, 2013filed Feb 11, 2014FY2012ended Dec 31, 2012filed Feb 15, 2013FY2011ended Dec 31, 2011filed Feb 17, 2012FY2010ended Dec 31, 2010filed Feb 18, 2011FY2009ended Dec 31, 2009filed Feb 26, 2010FY2008ended Dec 31, 2008filed Aug 4, 2009FY2007ended Dec 29, 2007filed Aug 4, 2009
Operating cash flow10,6399,10713,42616,17718,26515,86512,8488,8658,00710,1418,5398,1375,7836,6715,8564,7794,0353,9473,230
Capital expenditures2,8322,7813,0312,7272,5202,4372,4572,0371,9182,2242,3672,1361,9842,0301,8722,0052,5482,1801,805
Free cash flow (CFO − capex)7,8076,32610,39513,45015,74513,42810,3916,8286,0897,9176,1726,0013,7994,6413,9842,7741,4871,7671,425
Depreciation and amortization4,6064,5974,3664,2244,4864,4414,3712,7182,4792,4752,0921,9311,8701,7531,5681,4691,3891,2741,095
Share repurchases03,0232,0123,50000004,3614,4615,0014,0013,9764,3303,0011,5002,477235,370
Dividends paid3,3973,3733,1322,9072,6252,6242,6032,0382,0491,8401,5761,2881,097829674479439383323

Insider activity

Form 4 filings by officers, directors and 10% owners, November 1, 2024 to November 1, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$0
0 sales by 0 insiders; officers and directors $0
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$324M
8 sales by 2 insiders; officers and directors $324M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Jun 26, 2026Clark James DavidSVP, Cont & Chief Acct Officertax withholding454$90.98$41K27,606Jun 29, 2026
May 31, 2026Newman BrianEVP, Chief Financial Officertax withholding2,478$90.98$225K3,008Jun 1, 2026
May 31, 2026Compton-Phillips AmyEVP, Chief Medical Officertax withholding7,618$90.98$693K9,557Jun 1, 2026
May 21, 2026Aguirre FernandoDirectordisposition to issuer1,563$93.50$146K10,513May 22, 2026
May 21, 2026Robbins LarryDirectoropen-market saleindirect370,462$93.45$35M5MMay 21, 2026
May 20, 2026Aguirre FernandoDirectordisposition to issuer30,437$93.78$3M12,076May 22, 2026
May 20, 2026Robbins LarryDirectoropen-market saleindirect797,628$93.48$75M5MMay 21, 2026
May 20, 2026Robbins LarryDirectoropen-market saleindirect152,691$94.81$14M5MMay 21, 2026
May 20, 2026Robbins LarryDirectoropen-market saleindirect66,881$95.67$6M5MMay 21, 2026
May 20, 2026Robbins LarryDirectoropen-market saleindirect800$96.28$77K5MMay 21, 2026
May 19, 2026Robbins LarryDirectoropen-market saleindirect2M$94.45$187M6MMay 21, 2026
May 19, 2026Robbins LarryDirectoropen-market saleindirect151$95.18$14K6MMay 21, 2026
May 14, 2026Aguirre FernandoDirectoraward1,563$97.15$152K42,513May 15, 2026
May 14, 2026Balser Jeffrey R.Directoraward2,058$97.15$200K15,717May 15, 2026
May 14, 2026Kirby J ScottDirectoraward1,447$97.15$141K14,434May 15, 2026
May 14, 2026Norwalk Leslie VDirectoraward1,447$97.15$141K7,376May 15, 2026
May 14, 2026Sansone Guy PDirectoraward1,447$97.15$141K15,106May 15, 2026
May 14, 2026Brown C David IIDirectoraward1,544$97.15$150K129,316May 15, 2026
May 8, 2026Mandadi TilakEVP, Chief Exp & Tech Officeropen-market sale69,551$89.58$6M10,133May 11, 2026
Apr 1, 2026Shah Prem SEVP and Group Presidenttax withholding1,484$72.49$108K64,356Apr 2, 2026
Apr 1, 2026Nelson Steven HEVP and President, Aetnatax withholding2,432$72.49$176K2,900Apr 2, 2026
Apr 1, 2026Mandadi TilakEVP, Chief Exp & Tech Officertax withholding3,634$72.49$263K79,684Apr 2, 2026
Apr 1, 2026Khichi Samrat S.EVP, CPO and General Counseltax withholding3,541$72.49$257K33,421Apr 2, 2026
Apr 1, 2026Joyner J. DavidPresident, CEO and Chair, Directortax withholding8,029$72.49$582K70,349Apr 2, 2026
Apr 1, 2026Clark James DavidSVP, Cont & Chief Acct Officertax withholding3,262$72.49$236K15,457Apr 2, 2026

Full insider history for CVS Health, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
CVS HEALTH CORPORATION, CIK 64803 on EDGAR
Extract generated
August 27, 2026
Withheld
none
Repaired
1 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: income tax FY2025
XBRL concepts behind each line

Income statement

Revenue: Revenues
Cost of revenue: CostOfGoodsAndServicesSold, CostOfRevenue
Gross profit: GrossProfit
Research and development: not filed
Selling, general and administrative: not filed
Operating income: OperatingIncomeLoss
Other income (expense): OtherNonoperatingIncomeExpense
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAndAmortization, DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: PaymentsOfDividends

The data

The statements on this page as files, generated August 27, 2026.

JSON file
/data/financials/CVS.json